A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Iannazzo, Sergio; Colombatto, Piero; Ricco, Gabriele; Oliveri, Filippo; Bonino, Ferruccio; Brunetto, Maurizia R.
• Is Part Of: Digestive and liver disease. Volume 47:Issue 3(2015)
• Page Start: 249
• Page End: 254
• Publication Date: 2015-03
• Subjects: Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2014.12.008
• Languages: English
• ISSNs: 1590-8658

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <title id="sect0010">Background and aims</title> <p id="spar0005">Rapid virologic response is the best predictor of sustained virologic response with dual therapy in genotype-1 chronic hepatitis C, and its evaluation was proposed to tailor triple therapy in F0–F2 patients. Bio-mathematical modelling of viral dynamics during dual therapy has potentially higher accuracy than rapid virologic in the identification of patients who will eventually achieve sustained response. Study's objective was the cost-effectiveness analysis of a personalized therapy in naïve F0–F2 patients with chronic hepatitis C based on a bio-mathematical model (model-guided strategy) rather than on rapid virologic response (guideline-guided strategy).</p> </sec> <sec> <title id="sect0015">Methods</title> <p id="spar0010">A deterministic bio-mathematical model of the infected cell dynamics was validated in a cohort of 135 patients treated with dual therapy. A decision-analytic economic model was then developed to compare model-guided and guideline-guided strategies in the Italian setting.</p> </sec> <sec> <title id="sect0020">Results</title> <p id="spar0015">The outcomes of the cost-effectiveness analysis with model-guided and guideline-guided strategy were 19.1–19.4 and 18.9–19.3 quality-adjusted-life-years. Total per-patient lifetime costs were €25, 200–€26, 000 with model-guided strategy and €28, 800–€29, 900 with guideline-guided strategy. When comparing model-guided with guideline-guided strategy the former resulted more effective and less costly.</p> </sec> <sec> <title id="sect0025">Conclusions</title> <p id="spar0020">The adoption of the bio-mathematical predictive criterion has the potential to improve the cost-effectiveness of a personalized therapy for chronic hepatitis C, reserving triple therapy for those patients who really need it.</p> </sec> </abstract>